Actualités Uniqure Nv - 0EE0 | Actions London Stock Exchange

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Announced alignment with the U.S. Food and Drug Administration...

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its...

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the...

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing...

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s...

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Uniqure Nv (0EE0)

Outils de qualité professionnelle, pour des investisseurs individuels.

0EE0 Actualités

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Uniqure Nv (0EE0) Actualités

Uniqure Nv (0EE0)

Outils de qualité professionnelle, pour des investisseurs individuels.

0EE0 Actualités

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités